Bevacizumab-Augmented Retinal Laser Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Double-Masked Clinical Trial
Authors:
- 1 March 2008
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 18 (2) , 263-269
Abstract
Purpose: To evaluate the additional therapeutic effect of single intravitreal bevacizumab injection on standard laser treatment in the management of proliferative diabetic retinopathy. Methods: A prospective, fellow-eye sham controlled clinical trial was conducted on 80 eyes of 40 high-risk characteristic proliferative diabetic retinopathy type II diabetics. All cases received standard laser treatment according to Early Treatment Diabetic Retinopathy Study protocol. Avastin-assigned eyes received 1.25 mg intravitreal bevacizumab (Genentech Inc., San Francisco, CA) on the first session of their laser treatments. Fluorescein angiography was performed at baseline and at weeks 6 and 16, and proliferative diabetic retinopathy regression was evaluated in a masked fashion. Results: The median age was 52 years (range: 39–68) and 30% of the participants were male. All patients were followed for 16 weeks. A total of 87.5% of Avastin-injected eyes and 25% of sham group showed complete regression at week 6 of follow-up (pp<0.005). However, at week 16, PDR recurred in a sizable number of the Avastin-treated eyes, and the complete regression rate in the two groups became identical (25%; p=1.000); partial regression rates were 70% vs 65%. In the subgroup of Avastin-treated eyes, multivariate analysis identified hemoglobin A1c as the strongest predictor of proliferative diabetic retinopathy recurrence (p=0.033). Conclusions: Intravitreal bevacizumab remarkably augmented the short-term response to scatter panretinal laser photocoagulation in high-risk characteristic proliferative diabetic retinopathy but the effect was short-lived, as many of the eyes showed rapid recurrence. Alternative dosing (multiple and/or periodic intravitreal Avastin injections) is recommended for further evaluation.Keywords
This publication has 30 references indexed in Scilit:
- Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic IndividualsOphthalmology, 2006
- The Prevalence of Diabetic Retinopathy Among Adults in the United StatesArchives of Ophthalmology (1950), 2004
- Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primateAmerican Journal of Ophthalmology, 2002
- Intravitreous Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult PrimateOphthalmology, 1996
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.Proceedings of the National Academy of Sciences, 1995
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 1994
- Fundus Photographic Risk Factors for Progression of Diabetic RetinopathyOphthalmology, 1991
- Clinical and Experimental Studies on Retinal NeovascularizationAmerican Journal of Ophthalmology, 1982